Glomerulus

ZyVersa Therapeutics Announces a Publication in the Peer-Reviewed Journal, Aging, Linking Inflammasome NLRP3 Activation with Age-Related Structural Changes in the Kidney and Reduced Kidney Function

Retrieved on: 
Wednesday, October 18, 2023
ASC, Hypertrophy, Kidney, Inflammation, Research, Journal, Mouse, Enlargement, Chronic kidney disease, Glomerulosclerosis, Disease, Kidney disease, Focal segmental glomerulosclerosis, Scar, Genetic distance, Podocyte, Therapy, FSGS, Inflammasome, Glomerulus, Super Meat Boy, Pharmaceutical industry, Ageing, NLRP3

Age-related inflammasome signaling and its effects are compounded in the presence of kidney disease, leading to poorer outcomes.

Key Points: 
  • Age-related inflammasome signaling and its effects are compounded in the presence of kidney disease, leading to poorer outcomes.
  • ZyVersa is developing Inflammasome ASC Inhibitor IC 100 which can inhibit up to 12 different inflammasomes (including NLRP3 inflammasomes) and their associated ASC specks which perpetuate damaging inflammation.
  • Data demonstrate a critical role for NLRP3 inflammasomes in age-related kidney deterioration, which is exacerbated in the presence of kidney disease.
  • NLRP3 inflammasome signaling and its effects on podocytes may be a critical contributor to a lower threshold for developing kidney disease in older people.

Omeros Corporation Reports Second Quarter 2023 Financial Results

Retrieved on: 
Wednesday, August 9, 2023
Neurology, Biotechnology, Pharmaceutical, Oncology, Health, FDA, Clinical Trials, Other Health, DSM-IV codes, Survival, Tardive dyskinesia, Bangladesh Technical Education Board, Data analysis, Patent, Investment, Patient, Congress, BLA, Inflammation, Emory University, Therapy, Paroxysmal nocturnal hemoglobinuria, European Hematology Association, Research, Emory, Government, Proteinuria, Kidney International, CUD, Glomerulus, Manuscript, L-DOPA, Hematuria, Safety, Omeros, COVID-19, Inflammation Research, Immunoglobulin A, Fibrosis, PIN, Cancer, PNH, National Institute on Drug Abuse, LID, PDE7, Hemolysis, Complement, Clinical trial, Mannan-binding lectin, Sale, Trial of the century, IgA nephropathy, Corporation, NIDA, Society, C5, Pharmaceutical industry, Reinsurance, Music, Security (finance), Vaccine, Video game, Frontiers, Hematology, Immunology, Agency

“Our team continued building significant shareholder value throughout the second quarter of 2023,” said Gregory A. Demopulos, M.D., Omeros’ chairman and chief executive officer.

Key Points: 
  • “Our team continued building significant shareholder value throughout the second quarter of 2023,” said Gregory A. Demopulos, M.D., Omeros’ chairman and chief executive officer.
  • Total costs and expenses for the second quarter of 2023 were $40.9 million compared to $37.4 million for the second quarter of 2022.
  • Interest expense during the second quarter of 2023 was $7.9 million compared to $4.9 million during the prior year quarter.
  • During the second quarter of 2023, we earned $4.5 million in interest and other income compared to $0.7 million in the prior year quarter.

New KDOQI Commentary of 2021 KDIGO Clinical Practice Guideline for Glomerular Diseases Published

Retrieved on: 
Wednesday, June 21, 2023
Kidney disease, Guideline, Clinical trial, Doctor of Philosophy, Associate, MS, Boston University School of Public Health, American Journal, AJKD, Glomerulus, Nephrology, NKF, National Kidney Foundation, FASN, American Journal of Kidney Diseases, Health, MPH, Dietary supplement, Medical device, MD, Medicine

NEW YORK, June 21, 2023 /PRNewswire/ -- The National Kidney Foundation (NKF) and its Kidney Disease Outcomes Quality Initiative (KDOQI) are pleased to announce the publication of the KDOQI US Commentary on the 2021 KDIGO Clinical Practice Guideline for the Management of Glomerular Diseases. This new comprehensive review, published today in the American Journal of Kidney Disease (AJKD), finds generally broad agreement with the KDIGO guidelines.

Key Points: 
  • NEW YORK, June 21, 2023 /PRNewswire/ -- The National Kidney Foundation (NKF) and its Kidney Disease Outcomes Quality Initiative (KDOQI) are pleased to announce the publication of the KDOQI US Commentary on the 2021 KDIGO Clinical Practice Guideline for the Management of Glomerular Diseases.
  • The 2021 KDOQI Guideline on the Management of Glomerular Disease is a tour-de-force compendium for glomerular diseases.
  • The KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases marks a significant update to the previous set of recommendations published in 2012.
  • The KDOQI working group crafted a chapter-by-chapter companion article to provide specific commentary on the implementation of the KDIGO 2021 guidelines within the United States.

Northwell Announces $1.25M Endowed, First-of-its-Kind Kidney Fellowship

Retrieved on: 
Wednesday, July 20, 2022
Surgery, Hospitals, Philanthropy, Practice Management, Other Health, Managed Care, General Health, Fund Raising, Health, Foundation, Linda, Knowledge, Diabetes, Kidney disease, Education, Kidney, Physician, Feinstein Institute for Medical Research, Â, Twitter, Instagram, Hospital, LI, Glomerulus, Research, Donald, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Lupus, Hofstra University, Multimedia, Cancer, Leadership, MD, Medical research, Patient, LinkedIn, Health, Focal segmental glomerulosclerosis, Glomerulonephritis, Program, Nursing, Medicine, Pharmaceutical industry, Veterinary medicine, Northwell Health, Nephrology, Hypertension, Facebook

They will oversee the newly-created Galdi Fellowship in Onco-Nephrology and Glomerular Kidney Diseases.

Key Points: 
  • They will oversee the newly-created Galdi Fellowship in Onco-Nephrology and Glomerular Kidney Diseases.
  • Credit Northwell Health
    The newly created Galdi Fellowship in Onco-Nephrology and Glomerular Kidney Diseases, run through Northwells Division of Kidney Diseases and Hypertension , will start in July 2023 and focuses on onco-nephrology and glomerular kidney diseases, two rapidly advancing and highly related subspecialties that have seen a surge in need as the treatment of kidney disease grows more complex.
  • The creation of the Galdi Fellowship represents the next milestone along the merging path of these two closely related fields of kidney disease.
  • The Glomerular Disease Center at Northwell supports physicians and patients in this progressive and highly advanced academic field of nephrology.

Ping An AskBob Doctor's Deep Learning Model Improves Diagnosis of Kidney Disease

Retrieved on: 
Tuesday, August 4, 2020
Medical specialties, Kidney diseases, Anatomy, Glomerulus, Nephron, Kidney, Sickle cell nephropathy, Hypertensive kidney disease

The system uses deep learning, a type of machine learning, to identify certain types of kidney lesions and cells to help doctors diagnose kidney disease with greater accuracy.

Key Points: 
  • The system uses deep learning, a type of machine learning, to identify certain types of kidney lesions and cells to help doctors diagnose kidney disease with greater accuracy.
  • The ARPS focuses on the glomerulus, a tuft-like group of small blood vessels in the nephron, the structural unit in the kidney that filters blood and produces urine.
  • Identification of glomerular lesions and their structure is critical for diagnosis, treatment and prognosis evaluation in kidney disease.
  • The ARPS also achieved an extraordinary performance for glomerular lesion identification and classification with an average accuracy of 92.8%.